Signaturefd LLC Buys 742 Shares of Inhibrx, Inc. (NASDAQ:INBX)

Signaturefd LLC raised its stake in Inhibrx, Inc. (NASDAQ:INBX) by 4,637.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 758 shares of the company’s stock after acquiring an additional 742 shares during the period. Signaturefd LLC’s holdings in Inhibrx were worth $29,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. grew its position in Inhibrx by 389.8% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,471 shares of the company’s stock valued at $208,000 after acquiring an additional 4,354 shares during the period. Arizona State Retirement System bought a new stake in Inhibrx in the fourth quarter valued at $209,000. Fox Run Management L.L.C. bought a new stake in Inhibrx in the third quarter valued at $232,000. Exchange Traded Concepts LLC grew its position in Inhibrx by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 6,705 shares of the company’s stock valued at $255,000 after acquiring an additional 1,700 shares during the period. Finally, Hennion & Walsh Asset Management Inc. grew its position in Inhibrx by 89.5% in the third quarter. Hennion & Walsh Asset Management Inc. now owns 27,731 shares of the company’s stock valued at $509,000 after acquiring an additional 13,098 shares during the period. 82.46% of the stock is currently owned by institutional investors.

Inhibrx Price Performance

Shares of INBX stock opened at $34.15 on Friday. The stock’s fifty day moving average is $35.11 and its 200-day moving average is $30.81. The company has a debt-to-equity ratio of 4.78, a quick ratio of 5.25 and a current ratio of 5.24. The stock has a market capitalization of $1.79 billion, a PE ratio of -6.79 and a beta of 2.87. Inhibrx, Inc. has a 52 week low of $14.31 and a 52 week high of $39.79.

Inhibrx (NASDAQ:INBX) last announced its earnings results on Wednesday, February 28th. The company reported ($1.73) EPS for the quarter, missing the consensus estimate of ($1.07) by ($0.66). Inhibrx had a negative return on equity of 590.78% and a negative net margin of 13,408.95%. The business had revenue of $1.63 million for the quarter, compared to the consensus estimate of $0.10 million. Equities research analysts expect that Inhibrx, Inc. will post -4.34 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently commented on INBX shares. Lifesci Capital cut Inhibrx from an “outperform” rating to a “market perform” rating in a report on Tuesday, January 23rd. JMP Securities restated a “market perform” rating on shares of Inhibrx in a report on Tuesday, January 23rd.

About Inhibrx

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.